Endologix AFX或AFX2腔内移植物与其他装置行腹主动脉瘤腔内修复术后外科干预风险比较
基于Kaiser Permanente腔内支架移植物注册数据的匹配队列研究,纳入2011年1月1日至2017年12月31日初次行EVAR的腹主动脉瘤患者,AFX/AFX2组470例与其他高用量装置组940例匹配比较。AFX/AFX2组III型内漏、EVAR后1年以上翻修手术、破裂及动脉瘤相关死亡风险均更高。作者认为接受这些装置的患者EVAR后应密切监测。
要点
- AFX/AFX2组III型内漏风险显著高于其他装置组(HR 38.79)。
- AFX/AFX2组初次EVAR后1年以上翻修手术风险更高(HR 4.50)。
- AFX/AFX2组破裂(HR 6.52)和动脉瘤相关死亡(HR 2.43)风险更高。
核心结论
- 匹配队列研究中,初次EVAR使用Endologix AFX系统的患者较使用其他高用量装置的患者,多种纵向不良结局及动脉瘤相关死亡风险更高。
- 作者认为接受这些装置的患者EVAR后应密切监测。
研究设计与样本
- 匹配队列研究,使用Kaiser Permanente腔内支架移植物注册数据。
- 纳入2011年1月1日至2017年12月31日在该医疗系统内因腹主动脉瘤初次行EVAR、年龄≥18岁的患者。
- 治疗组为接受Endologix AFX或AFX2装置的患者(n=470),对照组合格患者为接受该医疗系统内三种其他高用量腔内移植物装置之一者(n=2122)。
- 按患者和手术特征以2:1倾向评分无放回匹配至接受Endologix装置的患者,最终匹配样本为AFX/AFX2组470例和其他装置组940例。
主要发现
- 与其他装置相比,AFX/AFX2的III型内漏风险更高(HR 38.79;95%CI 14.51-103.67)。
- AFX/AFX2初次EVAR后1年以上翻修手术风险更高(HR 4.50;95%CI 3.10-6.54)。
- AFX/AFX2破裂风险更高(HR 6.52;95%CI 1.73-24.63)。
- AFX/AFX2动脉瘤相关死亡风险更高(HR 2.43;95%CI 1.32-4.47)。
临床怎么用
- 作者认为接受这些装置的患者EVAR后应密切监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the risk for 90-day returns to care and long-term subsequent surgical interventions after primary endovascular aneurysm repair (EVAR) with an Endologix AFX Endovascular AAA System compared with three other high-volume endograft devices. METHODS: We conducted a matched cohort study using data from Kaiser Permanente's Endovascular Stent Graft Registry. Patients aged ≥18 years who underwent primary EVAR for AAA in the health care system from January 1, 2011, to December 31, 2017, comprised the eligible study sample. The treatment group included patients who received an Endologix AFX or AFX2 device (n = 470). Patients who received one of three other high-volume endograft devices used within the health care system comprised the eligible comparison group (n = 2122). These patients were 2:1 propensity score matched without replacement to patients who received an Endologix device based on a number of patient and procedural characteristics. After the application of matching, conditional logistic regression was used to evaluate the likelihood for 90-day emergency department visit and readmission. Cause-specific Cox regression was used to evaluate the long-term risk of endoleak, graft revision, secondary reintervention (not including revision), conversion to open repair, and rupture during follow-up. Cox proportional hazards regression was used to evaluate the risk of mortality (overall and aneurysm related). RESULTS: The final matched study sample included 470 patients who received an Endologix AFX or AFX2 device and 940 patients who received a different high-volume device. compared with the other devices, AFX/AFX2 had a higher risk for type III endoleak (hazard ratio [HR], 38.79; 95% confidence interval [CI], 14.51-103.67), revision surgery >1 year after the primary EVAR (HR, 4.50; 95% CI, 3.10-6.54), rupture (HR, 6.52; 95% CI, 1.73-24.63), and aneurysm-related mortality (HR, 2.43; 95% CI, 1.32-4.47) was observed with the use of AFX/AFX2. CONCLUSIONS: In our matched cohort study, patients who received an Endologix AFX System during their primary EVAR had a higher risk for several adverse longitudinal outcomes, as well as aneurysm-related mortality, when compared with patients who received other high-volume devices. Patients who have received these devices should be monitored closely after EVAR.
引用
- Prentice HA, Paxton EW, Harris JE, et al. Risk for surgical interventions following endovascular aneurysm repair with Endologix AFX or AFX2 Endovascular AAA Systems compared with other devices. J Vasc Surg. 2023. PMID: 37037259. doi:10.1016/j.jvs.2023.03.496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。